Fresenius Medical Care
920 Winter Street
Waltham
Massachusetts
02451
United States
Tel: 781-699-9000
Website: http://www.fmcna.com/
About Fresenius Medical Care
Fresenius Medical Care North America (FMCNA) is proud that our unwavering commitment to our patients has made us the global leader in dialysis healthcare. Our caring professionals touch the lives of over 160,000 patients and their families, combining innovative care with profound personal connections. We're the largest provider of renal care products and services in the nation, including state-of-the-art dialysis machines, dialyzers and pharmaceuticals. We're also home to the country's largest renal specialty laboratories. Every day, our professionals collaborate, challenge one another and ultimately make groundbreaking discoveries that change patients' lives for the better. FMCNA's dialysis care services include hemodialysis, home dialysis and transplant support services, and in-center services to provide our patients with unsurpassed personalized care.
The FMCNA team comprises over 55,000 dedicated employees in North America, all of whom are focused on a singular goal: delivering the highest-quality care to help patients with renal disease live the most fulfilling, rewarding lives possible.
Our facility in Concord CA is our exclusive site for research, development, manufacturing, warehousing and technical services for our durable medical device products including our hemodialysis machine (2008® as well as accessories and upgrade kits) and three peritoneal dialysis systems (Liberty®, Newton IQ® and Freedom Cycler® systems) currently in commercial production. The site is our first and oldest site in North America and was opened in 1986. The site was located in Walnut Creek CA for many years however in 2013 due to the need for significantly more space we relocated to a much larger facility in Concord CA investing in the site’s long-term future. All of the dialysis products used in North America are produced in North America.
Each of the employees working at our Concord plant has a profound commitment to the quality of the products we produce which directly ties into the quality of our patient care. Some faces have been with us since 1986 while others are new as we have grown every year since North American operations began. We are thrilled to have some additional products moving forward through development that will give our patients another treatment option.
http://jobs.fmcna.com/
168 articles about Fresenius Medical Care
-
Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources
3/13/2024
Fresenius Medical Care has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources.
-
Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador
3/5/2024
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announced the sale of its dialysis clinic networks in Brazil, Colombia, Chile and Ecuador to DaVita Inc. for a total transaction price of USD 300 million.
-
PatenSee and Fresenius Medical Care Sign Clinical Collaboration Agreement
2/13/2024
PatenSee, developer of a fistula monitoring system for dialysis patients, has entered into an agreement with Fresenius Medical Care, a leading global provider of dialysis services.
-
Fresenius Medical Care Brings Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S., demonstrating Global Leadership in Medical Device and Membrane Engineering Technologies
2/8/2024
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announced the company has received U.S. Food and Drug Administration 510 clearance for the company's 5008X Hemodialysis System.
-
Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board
2/5/2024
Fresenius Medical Care has nominated six employee representatives as members of the company's Supervisory Board.
-
Fresenius Medical Care Executes on Its Strategic Portfolio Optimization Program and Announces Key Transactions
1/8/2024
Fresenius Medical Care today announced updates from transactions in 2023 as part of the Company's ongoing Portfolio Optimization Program.
-
Fresenius Medical Care completes change of legal form into a German stock corporation
11/30/2023
Fresenius Medical Care announces the successful completion of its change of legal form from a partnership limited by shares into a German stock corporation as of November 30, 2023.
-
Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months and solid business outlook for the fourth quarter
11/1/2023
Our unwavering focus on executing against our strategic plan and the successful implementation of turnaround measures to date, continue to translate into improved operating performance.
-
Fresenius Medical Care appoints Craig Cordola as new Management Board member for Care Delivery
10/31/2023
Fresenius Medical Care has appointed Craig Cordola (52) as new Management Board member for the globally operating Care Delivery segment.
-
Fresenius Medical Care Achieves Key AI Milestone With First-Phase Completion of Largest Global Dialysis Clinical Dataset
10/26/2023
Fresenius Medical Care announced the phase-one completion of the company's first anonymized global dialysis dataset—coined the Apollo database project—the foundation of the company's long-term AI aspirations.
-
Fresenius Medical Care Announces FDA Clearance of Versi®HD with GuideMe Software
8/23/2023
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for Versi ® HD with GuideMe Software, a completely reinvented self-guided interface for the company's VersiHD chronic home hemodialysis.
-
Fresenius Medical Care successfully executes strategic plan and narrows guidance range due to strong operational performance in the first half of 2023
8/2/2023
Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "The second quarter makes evident that the execution against our strategic plan is fully on track.
-
Fresenius Medical Care simplifies corporate structure by converting into a German stock corporation
7/14/2023
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting.
-
Breakthrough Study Demonstrates that High-Dose Hemodiafiltration Treatment for Kidney Failure Patients Significantly Reduces Mortality Rates
6/20/2023
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, participated in groundbreaking research that demonstrates that the mortality rate among kidney failure patients can be significantly reduced through the utilization of high-dose hemodiafiltration technology.
-
Fresenius Medical Care takes action to close global health gaps, signs "Zero Health Gaps" Pledge at the World Economic Forum
1/20/2023
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has taken the Zero Health Gaps Pledge at the World Economic Forum in Davos, Switzerland.
-
Fresenius Medical Care North America, IKONA Health Receive Major Grant to Expand Virtual Reality Healthcare Education, Improve Access in Rural Mississippi
1/5/2023
Fresenius Medical Care North America, the nation's leading renal care provider, has won a major grant from the Mississippi Department of Health's Office of Rural Health and Primary Care to expand kidney education through virtual reality.
-
Fresenius Medical Care North America Announces FDA Clearance of New Heat Purification System for Hemodialysis Water with Industry-Leading Efficiency
11/3/2022
Fresenius Medical Care North America's (FMCNA) Renal Therapies Group announced today that the U.S. Food and Drug Administration (FDA) has cleared the AquaA™ water system, one of the industry's most efficient water purification systems available for hemodialysis.
-
Fresenius Medical Care North America Upgrades Liberty Select Peritoneal Dialysis Cycler with New Connected Health Capabilities
11/2/2022
Fresenius Medical Care North America, the nation's leading dialysis products company, announced the U.S. Food and Drug Administration 510 clearance upgrading the company's Liberty® Select Cycler to enable remote therapy management with the Kinexus® Therapy Management Platform.
-
NxStage from Fresenius Medical Care Launches Speedswap® for Critical Care Dialysis
8/25/2022
Fresenius Medical Care North America's (FMCNA) Renal Therapies Group today announced the availability of Speedswap ® , a new option for the NxStage ® System One ™ with NxView ™ that enables the changing of a flow-compromised dialysis filter without replacing the entire cartridge.
-
InterWell Health, Cricket Health, and Fresenius Health Partners Complete Three-Way Merger, Creating Premier, Value-based Kidney Care Provider
8/24/2022
InterWell Health announced it has completed a three-way merger between Fresenius Medical Care's value-based care division, Fresenius Health Partners; InterWell Health, a leading physician organization driving innovation in the kidney care industry; and Cricket Health, a provider of value-based kidney care with an industry-leading patient engagement and data platform.